GRP78

Bold Therapeutics to Present Best-in-Class Phase 2 Metastatic Colorectal Cancer Data at AACR 2023

Retrieved on: 
Thursday, April 13, 2023
DNA, Clinician Administered PTSD Scale, AACR, Cell death, Therapy, Unfolded protein response, Progression-free survival, Safety, American Association for Cancer Research, Multimedia, Large intestine, PFS, ASCO, Plasma, ROS, DNA repair, FOLFOX, Reactive oxygen species, Cancer, Clutch (eggs), UPR, Induced cell cycle arrest, IL-27, GRP78, ORR, Pharmaceutical industry, Online shopping, Patient

VANCOUVER, B.C., April 13, 2023 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced that it will present two posters – a clinical poster (#CT149) and a translational research poster (#2259) – at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 14 - 19, 2023 in Orlando, Florida.

Key Points: 
  • VANCOUVER, B.C., April 13, 2023 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced that it will present two posters – a clinical poster (#CT149) and a translational research poster (#2259) – at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 14 - 19, 2023 in Orlando, Florida.
  • "This robustly positive interim clinical data is a testament to the hard work and dedication of our team, our collaborators, clinical sites, investigators and patients.
  • Previous Phase 1b trial results, presented at ASCO 2022, demonstrated that BOLD-100 in combination with FOLFOX was generally safe and well-tolerated.
  • Additional Phase 2 safety and efficacy results in advanced gastric and bile duct cancer have been accepted for presentation at ASCO 2023 in June.

Bold Therapeutics Attending and Presenting at the BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences

Retrieved on: 
Friday, October 14, 2022
GRP78, Therapy, Conference, ASCO, Society, Patient, Induced cell cycle arrest, Unfolded protein response, Confidentiality, Annual general meeting, Multimedia, UPR, Cell death, ROS, Gastrointestinal cancer, Reactive oxygen species, DNA, FOLFOX, Breakthrough therapy, Cancer, View, DNA repair, Pharmaceutical industry, BC

VANCOUVER, BC, Oct. 14, 2022 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they are attending the BIO-Europe 2022 conference in Leipzig, Germany from October 24 26, as well as presenting at the BIO-Europe Virtual Conference from November 2 - 4.

Key Points: 
  • VANCOUVER, BC, Oct. 14, 2022 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they are attending the BIO-Europe 2022 conference in Leipzig, Germany from October 24 26, as well as presenting at the BIO-Europe Virtual Conference from November 2 - 4.
  • Bold Therapeutics presented initial data from this Phase 2 trial at the 2022 American Society of Cancer Oncology (ASCO) Annual Meeting in June 2022.
  • Consequently, Bold Therapeutics expects to receive a Breakthrough Therapy Designation in the treatment of 3rd line or later treatment-resistant metastatic colorectal cancer (mCRC) and potentially other gastrointestinal cancer indications as well.
  • Bold Therapeutics expects to present this robust data set at a major cancer conference in early 2023.

Bold Therapeutics' BOLD-100 Early mCRC Data to be Showcased at 2022 Metals in Medicine Gordon Research Conference

Retrieved on: 
Friday, June 24, 2022
DNA repair, ISCB Senior Scientist Award, CMC, ROS, Patient, UPR, Annual general meeting, PFS, Population, Industry, FOLFOX, Reactive oxygen species, Bladder cancer, GRP78, Induced cell cycle arrest, Metal, Compound, Unfolded protein response, Cancer, Therapy, Confidentiality, Bortezomib, Gordon Research Conferences, Trifluridine, Progression-free survival, Gordon, DNA, Use, Multiple myeloma, Amgen, Takeda, Bayer, Research, Society, Conference, ASCO, Cell death, Pharmaceutical industry, BC, Medicine

VANCOUVER, BC, June 24, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they will be attending the Metals in Medicine Gordon Research Conference focusing on Advancing the Use of Metal-Based Compounds and Nanotheranostics for Personalized Medicine.

Key Points: 
  • VANCOUVER, BC, June 24, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they will be attending the Metals in Medicine Gordon Research Conference focusing on Advancing the Use of Metal-Based Compounds and Nanotheranostics for Personalized Medicine.
  • Adam Carie, Director of CMC & Nonclinical Development, will be presenting on behalf of Bold Therapeutics in the "Clinical Advances for Metals in Medicine" session.
  • "Bold Therapeutics is excited to present these remarkable results at the Gordon Research Metals in Medicine Conference showcasing the cutting-edge, multi-disciplinary work being performed at Vancouver-based Bold Therapeutics" noted Dr. Carie.
  • For more information about Bold Therapeutics, please visit: https://www.bold-therapeutics.com/
    For more information about the Gordon Research Conference, please visit:

Bold Therapeutics Extends South Korea Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic

Retrieved on: 
Thursday, January 13, 2022
GRP78, Stomach, National Cancer Center, Samsung Medical Center, Reactive oxygen species, Unfolded protein response, Cancer, Douglas BTD Destroyer, CEO, ROS, UPR, DNA, Therapy, Odds, Seoul National University Hospital, DNA repair, Induced cell cycle arrest, Emphasis (typography), FOLFOX, Cell death, FDA, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 13, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement with an undisclosed publicly traded South Korean biopharmaceutical company, originally executed in May 2020, for development and commercialization rights to BOLD-100 in South Korea.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 13, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement with an undisclosed publicly traded South Korean biopharmaceutical company, originally executed in May 2020, for development and commercialization rights to BOLD-100 in South Korea.
  • Bold Therapeutics' BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest.
  • "As our partner is one of the fastest growing and most respected pharmaceutical companies in South Korea, we are honored to extend this option agreement that allows us to further leverage their substantial expertise in oncology development," said E. Russell McAllister, CEO of Bold Therapeutics.
  • For more information about Bold Therapeutics, please visit the company's website at www.bold-therapeutics.com